Nusinersen
Brand names: Spinraza · Active ingredient: Nusinersen
In short: SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
What is Nusinersen used for?
SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Nusinersen dosage
SPINRAZA is administered intrathecally by, or under the direction of, healthcare professionals experienced in performing lumbar punctures.
Two dosing regimen options for SPINRAZA, which consist of loading followed by maintenance dosages, are presented in Table 1.
Loading Dosages | Maintenance Dosage
Low Dose Regimen
(Low dose with four loading doses) | Administer a total of four loading doses as follows:
one 12 mg dose every 14 days for three doses, then
a fourth 12 mg dose 30 days after the third dose. | Administer 12 mg once every 4 months starting 4 months after the last loading dose.
High Dose Regimen
(High dose with two loading doses) | Administer a total of two loading doses as follows:
one 50 mg dose followed by a second 50 mg dose 14 days later. | Administer 28 mg once every 4 months starting 4 months after the last loading dose.
Missed Dose of Low Dose Regimen
Missed Loading Dose
If a 12 mg loading dose (any of the 4 loading doses) is missed, administer the missed loading dose as soon as possible; adjust the date for the subsequent doses to maintain the recommended interval between doses.
Missed Maintenance Dose
Less than 8 months from last maintenance dose
Administer the missed 12 mg maintenance dose as soon as possible; then administer the next maintenance dose per the originally scheduled date, as long as these two doses are administered at least 14 days apart.
At least 8 months but less than 16 months from last maintenance dose
Administer the missed 12 mg maintenance dose as soon as possible, followed by one additional dose 14 days later, and then administer the next maintenance dose 4 months thereafter.
At least 16 months but less than 40 months from last maintenance dose
Administer the missed 12 mg maintenance dose as soon as possible, followed by two additional doses 14 days apart, and then administer the next maintenance dose 4 months thereafter.
At least 40 months from last dose
Restart Low Dose Regimen with 12 mg loading dosesas described in Recommended Dosage.
Missed Dose of High Dose Regimen
Missed Second 50 mg Loading Dose
Administer the missed 50 mg loading dose as soon as possible; then administer 28 mg maintenance doses every 4 months thereafter.
Missed 28 mg Maintenance Dose
Less than 8 months from last maintenance dose
Administer the missed 28 mg maintenance dose as soon as possible; administer the next 28 mg maintenance dose per the originally scheduled date, as long as these two doses are administered at least 14 days apart; then administer 28 mg every 4 months thereafter.
At least 8 months to less than 40 months from last maintenance dose
Administer a 50 mg loading dose as soon as possible; then administer 28 mg maintenance doses every 4 months thereafter. …
How to take Nusinersen — instructions & advice from the label
Thrombocytopenia and Coagulation Abnormalities
Inform patients and caregivers that SPINRAZA could increase the risk of bleeding. Inform patients and caregivers of the importance of obtaining blood laboratory testing at baseline and prior to each dose to monitor for signs of increased potential for bleeding. Instruct patients and caregivers to seek medical attention if unexpected bleeding occurs .
Renal Toxicity
Inform patients and caregivers that SPINRAZA could cause renal toxicity. Inform patients and caregivers of the importance of obtaining urine testing at baseline and prior to each dose to monitor for signs of potential renal toxicity .
60110-01
Manufactured for:BiogenCambridge, MA 02142SPINRAZA is a registered trademark of Biogen.© Biogen 2016-2026
Warnings & precautions
Do not take this medicine if: None.
Coagulation abnormalities and thrombocytopenia, including acute severe thrombocytopenia, have been observed after administration of some antisense oligonucleotides.
In the sham-controlled studies for patients with infantile-onset (Study 1) and later-onset (Study 2) SMA who received Low Dose Regimen , 24 of 146 (16%) SPINRAZA-treated patients with high, normal, or unknown platelet count at baseline developed a platelet level below the lower limit of normal, compared to 10 of 72 (14%) sham-controlled patients.
In Study 2, two SPINRAZA-treated patients developed platelet counts less than 50,000 cells per microliter, with a lowest level of 10,000 cells per microliter recorded on study day 28.
In patients who received High Dose Regimen, decreases in platelet counts were also observed.
Because of the risk of thrombocytopenia and coagulation abnormalities from SPINRAZA, patients may be at increased risk of bleeding complications.
Perform a platelet count and coagulation laboratory testing at baseline and prior to each administration of SPINRAZA and as clinically needed.
Renal toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides.
SPINRAZA is present in and excreted by the kidney . In Study 1 and Study 2, 71 of 123 (58%) of SPINRAZA-treated patients had elevated urine protein, compared to 22 of 65 (34%) sham-controlled patients. Conduct quantitative spot urine protein testing (preferably using a first morning urine specimen) at baseline and prior to each dose of SPINRAZA. For urinary protein concentration greater than 0.2 g/L, consider repeat testing and further evaluation.
Nusinersen side effects
The following serious adverse reactions are described in detail in other sections of the labeling:
Thrombocytopenia and Coagulation Abnormalities
Renal Toxicity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of SPINRAZA cannot be directly compared to rates in clinical trials of other drugs and may not reflect the rates observed in practice.
SPINRAZA Low Dose Regimen (12 mg loading doses/12 mg maintenance doses)
In clinical studies, 385 patients (47% male, 68% Caucasian, and 12% Asian) were treated with SPINRAZA Low Dose Regimen , including 353 exposed for at least 6 months, 314 exposed for at least 1 year, and 256 exposed for at least 5 years.
Clinical Trial in Infantile-Onset SMA (Study 1)
In Study 1, baseline disease characteristics were largely similar in the SPINRAZA-treated patients and sham-control patients except that SPINRAZA-treated patients at baseline had a higher percentage compared to sham-control patients of paradoxical breathing (89% vs 66%), pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%).
The most common adverse reactions that occurred in at least 20% of SPINRAZA-treated patients and occurred at least 5% more frequently than in control patients were lower respiratory infection and constipation. …
About this medicine
Nusinersen is a modified antisense oligonucleotide, where the 2'-hydroxy groups of the ribofuranosyl rings are replaced with 2'-O-2-methoxyethyl groups and the phosphate linkages are replaced with phosphorothioate linkages. Nusinersen binds to a specific sequence in the intron downstream of exon 7 of the SMN2 transcript. The structural formula is:
SPINRAZA is supplied as a sterile, preservative-free, colorless solution for intrathecal use in a single-dose glass vial in the following strengths:
12 mg/5 mL (2.4 mg/mL)
28 mg/5 mL (5.6 mg/mL)
50 mg/5 mL (10 mg/mL)
Each 1 mL solution of the 12 mg/5 mL strength contains 2.4 mg of nusinersen (equivalent to 2.53 mg of nusinersen sodium salt). Each 1 mL also contains calcium chloride dihydrate (0.21 mg) USP, magnesium chloride hexahydrate (0.16 mg) USP, potassium chloride (0.22 mg) USP, sodium chloride (8.77 mg) USP, sodium phosphate dibasic anhydrous (0.10 mg) USP, sodium phosphate monobasic dihydrate (0.05 mg) USP, and Water for Injection USP. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID dd70cd5f-b0fc-4ba4-a5ea-89a34778bd94. Read the full official label on DailyMed.